ALTEOGEN (196170) Q3 2024 earnings summary

Executive summary

• Focuses on biopharmaceutical R&D, leveraging proprietary platform technologies for biosimilars, biobetters, and novel biologics, with a business model centered on licensing, milestone payments, and royalties.

• Major revenue drivers include technology licensing (ALT-B4), milestone payments, and product development partnerships with global pharma companies.

• Recent product approvals and new licensing deals have strengthened the pipeline and global reach.

Financial highlights

• 2024 Q3 consolidated revenue: ₩52.0B, down from ₩96.5B in 2023 Q3, reflecting milestone timing and licensing cycles.

• Operating profit for 2024 Q3: ₩2.4B, a turnaround from a ₩9.7B loss in 2023 Q3.

• Net income for 2024 Q3: ₩8.3B, compared to a net loss of ₩3.6B in 2023 Q3.

• R&D expenses remain high, at ₩42.2B YTD (81.3% of sales), reflecting ongoing pipeline investment.

• Cash and equivalents at Q3-end: ₩27.0B; total assets: ₩299.4B; equity ratio improved to 59.3%.

Outlook and guidance

• Expects continued revenue volatility due to milestone-based licensing model.

• Anticipates further product approvals and new licensing deals in 2025, with ongoing global clinical trials.

• R&D intensity to remain high as pipeline advances toward commercialization.